Clinical Trial Update: Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Niaspan for dyslipidemia in patients with diabetic nephropathy was terminated. Results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetic Nephropathy
• Hyperlipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Niaspan (niacin (nicotinic acid))

Snippet

Sponsor: University of Miami | Conditions: Diabetes Mellitus, Type 2, Kidney Failure, Chronic | Phase 3 | Status: TERMINATED | Results posted: 2016-05-12